Использовать или не использовать препараты гидроксиэтилкрахмала в современных программах инфузионной терапии?

1. Свиридов С.В., Николаев Д.В., Гафоров Д.А. Дегидратация и методы контроля за проводимой инфузионной терапией. Cons. Med. Хирургия. (Прил.). М., 2008; 1.
2. Bapat PP, Raine GJ. Fluid resuscitation with colloid or crystalloid solutions. Use of dextran-70 for fluid resuscitation has been dying out (letter). Br Med J 1998; 317: 278.
3. Brandstrup B. Fluid therapy for the surgical patient. Best Pract Res Clin Anaesthesiol 2006; 20: 265–83.
4. Bartels C, Hadzik B, Abel M, Roth B. Renal failure associated with unrecognized hyperoncotic states after pediatric heart surgery. Intensive Care Med 1996; 22: 492–4.
5. Boldt J, Brosch C, Rohm K et al. Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in elderly cardiac surgery patients. Br J Anaesth 2008; 100: 457–64.
6. Boldt J, Brosch C, Rohm K et al. Is albumin administration in hypoalbuminemic elderly cardiac surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kidney function? Anesth Analg 2008; 107: 1496–503.
7. Boldt J, Schoëlhorn T, Mayer J et al. The value of an albumin-based intravascular volume replacement strategy in elderly patients undergoing major abdominal surgery. Anesth Analg 2006; 103: 191–9.
8. Brunkhorst FM, Engel C, Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Eng J Med 2008; 358: 125–39.
9. Cittanova ML, Leblanc I, Legendre C et al. Effect of hydroxyethyl starch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 1620–2.
10. Zhang J, Qiao H, He Z et al. Intraoperative fluid management inopen gastrointestinal surgery: goal-directed versus restrictive. Clinics (Sao Paulo) 2012; 67: 1149–55.
11. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Br Med J 1998; 317: 235–40.
12. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septics hock. Crit Care Med 2008; 36: 296–327.
13. Dieterich HJ, Weissmuller T, Rosenberger P, Eltzschig HK. Effect of hydroxyethyl starch on vascular leak syndrome and neutrophil accumulation during hypoxia. Crit Care Med 2006; 34: 1775–82.
14. Editors-in-Chief Statement Regarding Published Clinical Trials Conducted without IRB Approval by Joachim Boldt 2011.
15. Gan TJ, Soppitt A, Maroof M et al. Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. Anesthesiology 2002; 97: 820–6.
16. Gosling P. Fluid resuscitation with colloid or crystalloid solutions. Newer synthetic colloids should not be abandoned (letter). Br Med J 1998; 317: 277.
17. Hankeln K, Beez M. Haemodynamic and oxygen transport correlates of various volume substitutes in critically ill in-patients with various aetiologies of haemodynamic instability. Int J Intensive Care 1998; 5: 8–14.
18. Jacob L, Heming N, Guidet B. Hydroxyethyl starch and renal dysfunction. Transfusion Alternatives in Transfusion Medicine. 2007; 9 (3): 182–8.
19. Jung F, Koscielny J, Mrowietz C et al. The effect of molecular structure of hydroxylethyl starch on the elimination kinetics and fluidity of blood in human volunteers. Arzneimittelforschung 1993; 43: 99–105.
20. Kuze S, Ito Y, Miyahara T. Expiration of radioactive carbon dioxide by rats after administration of isotopic lactate and acetate. Acta Medica Biologica 1986; 34: 93–102.
21. Legendre C, Thervet E, Page B et al. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993; 342: 238–9.
22. Macintyre E, Mackie IJ, Ho D et al. The haemostatic effects of hydroxyethyl starch (HES) used as a volume expander. Intensive Care Med 1985; 11: 300–3.
23. Makin A, Plenderleith L. Fluid resuscitation with colloid or crystalloid solutions. One conclusion could be that hypertonic saline is better than colloids in trauma (letter). Br Med J 1998; 317: 277–8.
24. McAnulty GR, Grounds RM. Fluid resuscitation with colloid or crystalloid solutions. Eight studies should have been excluded (letter). Br Med J 1998; 317: 278–9.
25. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368–77.
26. Schortgen F, Lacherade JC, Bruneel F et al. Effects of hydroxylethylstarch and gelatin on renal function in severe sepsis: A multicentre randomised study. Lancet 2001; 357: 911–6.
27. Schortgen F, Girou E, Deye N, Brochard L. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008; 34: 2157–68.
28. Svensén C, Hahn RG. Volume kinetics of Ringer solution, dextran 70, and hypertonic saline in male volunteers. Anesthesiology 1997; 87: 204–12.
29. Treib J, Haass A, Pindur G et al. HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995; 74: 1452–6.
30. Treib J, Haass A, Pindur G et al. Influence of intravascular molecular weight of hydroxyethyl starch on platelets. Eur J Haematol 1996; 56: 168–72.
31. Westphal M, James MFM, Kozek-Langenecker S et al. Hydroxyethyl Starches: Different Products – Different Effects. Anesthesiology 2009; 111 (1): 187–202.
32. Winkelmayer WC, Glynn RJ, Levin R, Avorn J. Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney Int 2003; 64: 1046–9.
33.Wyncoll DLA, Beale RJ, McLuckie A. Conditions and patient groups were too heterogeneous to allow meaningful comparisons (letter). Br Med J 1998; 317: 278–9.
34. Yuruk K, Almac E, Ince C. Hydroxyethyl starch solutions and their effect on the microcirculation and tissue oxygenation. Transfusion Alternatives in Transfusion Medicine 2007; 9 (3): 164–72.
35. Sakr Y, Payen D, Reinhart K et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007; 98: 216–24.
36. Perner A, Haase N, Guttormsen AB et al. Hydroxyethyl Starch130/0.4 versus Ringer's Acetate in Severe Sepsis. N Engl J Med 2012; 367 (2): 124–34. Erratum in: N Engl J Med 2012; 367 (5): 481.
37. Guidet B, Martinet O, Boulain T et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care London 2012; 16 (3): R94.
38. Myburgh JA, Finfer S, Bellomo R et al. Hydroxyethyl starch or saline for fluidresuscitation in intensive care. N Engl J Med 2012; 367 (20): 1901–11.
39. Brunkhorst FM, Engel C, Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125–39.

Е.Ю.Халикова

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России